{"url": "https://www.who.int/csr/don/2002_05_17/en/", "date_of_publication": "2002-05-17", "headline": "2002 - Meningococcal disease in Burkina Faso - Update 6", "main_text": "As of\u00a0 15 May 2002, 12 587 cases, including 1 447 deaths have been reported to WHO.\u00a0 The downward trend in the epidemic noted in the report of 6 May is continuing, with 1 district, Paul VI, remaining above the epidemic threshold. The following measures continue to be taken by Le Comit\u00e9 National de Pilotage pour la M\u00e9ningite (Crisis Committee): epidemiological surveillance, laboratory confirmation of suspected cases and case management. Since the emergence of meningococcal serogroup W135 in Burkina Faso has major implications for public health in the African continent, a research agenda has been agreed by the Crisis Committee. \u00a0 The research is being implemented by a team consisting of WHO, Epicentre, WHO Collaborating Centre for Reference and Research on Meningococci, Oslo, Norway, Centers for\u00a0Disease Control and Prevention (CDC, Atlanta, United States ) and l'Association pour la M\u00e9decine pr\u00e9ventive (AMP).\u00a0\u00a0\u00a0 The topics include: a detailed description and evaluation of the risk factors of the current epidemic; an ecological analysis of association between vaccine coverage and epidemics; N. meningitidis seroprevalence and carriage; and the socioeconomic impact of the epidemic. The team is also assessing the feasibility of estimating immunogenicity and efficacy of tetravalent vaccine.", "key_terms": ["epidemic"]}